Related Experiment Videos
In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands
1Hematology/Oncology Division, Massaohusetts General Hospital Cancer Center, Boston 02114, USA.
Abstract:
The Mpl ligands are a family of closely related hematopoietic growth factors that bind to the thrombopoietin receptor, c-Mpl. In addition to the endogenous Mpl ligand, thrombopoietin, two recombinant Mpl ligands, recombinant thrombopoietin and pegylated megakaryocyte growth and development factor (PEG-MGDF) are under investigation. Endogenous thrombopoietin regulates most of the normal production of platelets but also is essential for the normal development of other lineages. When recombinant thrombopoietin or PEG-MGDF is administered to normal animals or humans, there is a dose-dependent increase in the platelet count but no effect on leukocytes or erythrocytes. When administered following chemotherapy in animal models or humans, Mpl ligands reduce the duration and sometimes the degree of thrombocytopenia. The Mpl ligands also may be effective in reducing the thrombocytopenia of patients with HIV infection, liver disease, myelodysplasia, or after plateletpheresis.
Insights
Mpl ligands, including thrombopoietin and PEG-MGDF, effectively increase platelet counts and reduce thrombocytopenia following chemotherapy. These hematopoietic growth factors show promise for various medical conditions.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Mpl ligands are hematopoietic growth factors that bind to the thrombopoietin receptor (c-Mpl).
- Endogenous thrombopoietin is crucial for platelet production and development of other blood cell lineages.
- Recombinant Mpl ligands, including recombinant thrombopoietin and PEG-MGDF, are being investigated for therapeutic applications.
Purpose of the Study:
- To evaluate the effects of recombinant Mpl ligands on platelet production and thrombocytopenia.
- To assess the safety and efficacy of Mpl ligands in normal subjects and in models of chemotherapy-induced thrombocytopenia.
Main Methods:
- Administration of recombinant thrombopoietin and PEG-MGDF to normal animals and humans.
- Evaluation of Mpl ligand administration following chemotherapy in animal models and human subjects.
Main Results:
- Recombinant thrombopoietin and PEG-MGDF administration resulted in a dose-dependent increase in platelet counts in normal subjects.
- No significant effects on leukocyte or erythrocyte counts were observed.
- Mpl ligands reduced the duration and severity of thrombocytopenia in chemotherapy settings.
- Potential efficacy in conditions like HIV infection, liver disease, myelodysplasia, and post-plateletpheresis.
Conclusions:
- Mpl ligands are effective in stimulating platelet production and mitigating thrombocytopenia.
- These agents hold therapeutic potential for managing various causes of low platelet counts.
- Further investigation is warranted for their use in specific patient populations.